Gyre Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļGYRE
āļāļ·āđāļāļāļĢāļīāļĐāļąāļGyre Therapeutics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļApr 12, 2006
āļāļĩāļāļĩāđāļZhang (Ping)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ574
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļApr 12
āļāļĩāđāļāļĒāļđāđ12770 High Bluff Drive, Suite 150
āđāļĄāļ·āļāļSAN DIEGO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ92130
āđāļāļĢāļĻāļąāļāļāđ18585677770
āđāļ§āđāļāđāļāļāđhttps://www.gyretx.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļGYRE
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļApr 12, 2006
āļāļĩāļāļĩāđāļZhang (Ping)
Mr. Songjiang Ma
President, Director
Dr. Ying Luo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Ying Luo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Ying Luo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Weiguo Ye
Chief Operating Officer
Mr. Weiguo Ye
Chief Operating Officer
Mr. Weiguo Ye
Chief Operating Officer
Ms. Ruoyu Chen
Chief Financial Officer
Mr. Maxwell (Max) Kirkby
Director
Dr. Yue Xiong, Ph.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Songjiang Ma
President, Director
Dr. Ying Luo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Ying Luo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Dr. Ying Luo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Weiguo Ye
Chief Operating Officer
Mr. Weiguo Ye
Chief Operating Officer